37,822 Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT) Bought by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC bought a new position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 37,822 shares of the company's stock, valued at approximately $3,045,000. Gilder Gagnon Howe & Co. LLC owned about 0.07% of PROCEPT BioRobotics as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PRCT. FMR LLC boosted its holdings in PROCEPT BioRobotics by 11.9% in the fourth quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after acquiring an additional 866,328 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after acquiring an additional 297,075 shares during the period. Alliancebernstein L.P. grew its position in shares of PROCEPT BioRobotics by 14.2% during the 4th quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock valued at $141,110,000 after acquiring an additional 218,148 shares during the period. Wellington Management Group LLP boosted its position in shares of PROCEPT BioRobotics by 38.8% in the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after purchasing an additional 416,819 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in PROCEPT BioRobotics by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 1,164,037 shares of the company's stock worth $93,751,000 after purchasing an additional 57,449 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Stock Performance

PRCT stock traded up $2.89 during trading on Friday, hitting $55.74. The company had a trading volume of 384,393 shares, compared to its average volume of 806,121. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.08 billion, a PE ratio of -28.55 and a beta of 1.09. The firm has a 50-day moving average price of $56.89 and a 200-day moving average price of $73.47. PROCEPT BioRobotics Co. has a 1-year low of $47.04 and a 1-year high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.04. The business had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.51) EPS. On average, analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on PRCT shares. Bank of America lowered their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Friday, April 25th. Truist Financial cut their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Finally, Morgan Stanley cut their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $90.00.

Insiders Place Their Bets

In related news, CFO Kevin Waters sold 733 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company's stock, valued at approximately $6,161,966.46. The trade was a 0.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock valued at $368,322 in the last ninety days. Corporate insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).